Toll-like receptor 2 promotes breast cancer progression and resistance to chemotherapy

Toll-like receptor 2 promotes breast cancer progression and resistance to chemotherapy

Cancer stem cells (CSCs) are the main drivers of disease progression and chemotherapy resistance in breast cancer. Tumor progression and chemoresistance might then be prevented by CSC-targeted therapies. We previously demonstrated that Toll-like Receptor (TLR)2 is overexpressed in CSCs and fuels the...

Full description

Bibliographic Details
Main Authors: Antonino Di Lorenzo, Elisabetta Bolli, Roberto Ruiu, Giuseppe Ferrauto, Enza Di Gregorio, Lidia Avalle, Aurora Savino, Pietro Poggio, Irene Fiore Merighi, Federica Riccardo, Mara Brancaccio, Elena Quaglino, Federica Cavallo, Laura Conti
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:OncoImmunology
Subjects:
Breast cancer
Toll-like receptor 2
HER2
HMGB1
chemoresistance
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2022.2086752

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2022.2086752

Similar Items